462 related articles for article (PubMed ID: 14705108)
1. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
Burstein R; Collins B; Jakubowski M
Ann Neurol; 2004 Jan; 55(1):19-26. PubMed ID: 14705108
[TBL] [Abstract][Full Text] [Related]
2. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
Jakubowski M; Levy D; Goor-Aryeh I; Collins B; Bajwa Z; Burstein R
Headache; 2005; 45(7):850-61. PubMed ID: 15985101
[TBL] [Abstract][Full Text] [Related]
3. Clarification of developing and established clinical allodynia and pain-free outcomes.
Landy SH; McGinnis JE; McDonald SA
Headache; 2007 Feb; 47(2):247-52. PubMed ID: 17300364
[TBL] [Abstract][Full Text] [Related]
4. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
Burstein R; Jakubowski M
Ann Neurol; 2004 Jan; 55(1):27-36. PubMed ID: 14705109
[TBL] [Abstract][Full Text] [Related]
5. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism based prevention and treatment of migraine].
Sakai F
Rinsho Shinkeigaku; 2004 Nov; 44(11):809-11. PubMed ID: 15651298
[TBL] [Abstract][Full Text] [Related]
7. Difference in triptan effect in patients with migraine and early allodynia.
Lampl C; Huber G; Haas S; Rittberger E; Diener HC
Cephalalgia; 2008 Oct; 28(10):1031-8. PubMed ID: 18624801
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
9. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.
Schoenen J; De Klippel N; Giurgea S; Herroelen L; Jacquy J; Louis P; Monseu G; Vandenheede M;
Cephalalgia; 2008 Oct; 28(10):1095-105. PubMed ID: 18644036
[TBL] [Abstract][Full Text] [Related]
10. Early treatment of migraine with rizatriptan: a placebo-controlled study.
Mathew NT; Kailasam J; Meadors L
Headache; 2004; 44(7):669-73. PubMed ID: 15209688
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
Linde M; Mellberg A; Dahlöf C
Cephalalgia; 2006 Feb; 26(2):113-21. PubMed ID: 16426264
[TBL] [Abstract][Full Text] [Related]
12. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference.
Pascual J; García-Moncó C; Roig C; Yusta Izquierdo A; López-Gil A;
Headache; 2005 Oct; 45(9):1140-50. PubMed ID: 16178944
[TBL] [Abstract][Full Text] [Related]
13. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
14. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
15. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.
Cady RK; Freitag FG; Mathew NT; Elkind AH; Mao L; Fisher AC; Biondi DM; Finlayson G; Greenberg SJ; Hulihan JF
Headache; 2009 Mar; 49(3):350-63. PubMed ID: 19220503
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
17. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
18. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.
Baos V; Serrano A; Torrecilla M; Bertral C; Caloto MT; Nocea G; Gerth WC;
Int J Clin Pract; 2003 Nov; 57(9):761-8. PubMed ID: 14686564
[TBL] [Abstract][Full Text] [Related]
20. An association between migraine and cutaneous allodynia.
Burstein R; Yarnitsky D; Goor-Aryeh I; Ransil BJ; Bajwa ZH
Ann Neurol; 2000 May; 47(5):614-24. PubMed ID: 10805332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
